Holen Sie sich die Stockscreener-App
3.20
3.32%
-0.11
Aclarion Inc Aktie (ACON) Neueste Nachrichten
Aclarion establishes second trial agreement with Weill Cornell By Investing.com - Investing.com Canada
Aclarion announces second commercial agreement with Weill Cornell Medicine - marketscreener.com
Weill Cornell adds Aclarion scan to 2-year spine surgery trial - Stock Titan
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine - The Manila Times
Aclarion announces $2.5M stock repurchase plan - MSN
Aclarion reports cash runway to ops into late 2027 - BizWest
Aclarion Reports 196% Annual Scan Volume Growth in Q1 2026, Fueled by Accelerating Clinical Adoption of Nociscan - MEXC Exchange
Aclarion reports 196% jump in Nociscan scan volumes in Q1 - Investing.com UK
Aclarion reports 196% jump in Nociscan scan volumes in Q1 By Investing.com - Investing.com Australia
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption - The Manila Times
Back-pain scan use rose 196% as Aclarion funds operations into 2027 - Stock Titan
Aclarion names Daniel Keefe as commercial director for Western US - Medical Buyer
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued ... - Bluefield Daily Telegraph
Aclarion, Inc. Appoints Daniel Keefe as Commercial Director, Western U.S - marketscreener.com
Aclarion (NASDAQ: ACON) expands 2022 equity plan in 2026 shareholder proxy - Stock Titan
Aclarion authorizes $2.5 million share buyback program By Investing.com - Investing.com India
Aclarion Launches $2.5 Million Share Repurchase Program - The Globe and Mail
Aclarion Announces $2.5 Million Stock Repurchase Plan - Ortho Spine News
Aclarion, Inc. announces an Equity Buyback for $2.5 million worth of its shares. - marketscreener.com
Aclarion authorizes $2.5 million share buyback program - Investing.com
Aclarion authorizes $2.5M share repurchase plan to deploy cash and support Nociscan growth - TradingView
Aclarion (NASDAQ: ACON) launches $2.5M share buyback plan - Stock Titan
With $19M cash, Aclarion plans buybacks while funding Nociscan - Stock Titan
Aclarion, Inc. authorizes a Buyback Plan. - marketscreener.com
Aclarion (ACON) Stock Insider Buying (Eye on Rally) 2026-04-20Community Watchlist - Xã Vĩnh Công
Aclarion receives patent for AI-based pain evaluation platform By Investing.com - Investing.com India
Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain - The Manila Times
Aclarion receives patent for AI-based pain evaluation platform - Investing.com
Aclarion, Inc. Secures U.S. Patent for AI-Enhanced Machine Learning Platform in Chronic Low Back Pain Diagnosis - Quiver Quantitative
New Aclarion patent targets faster, more consistent chronic back-pain scans - Stock Titan
Aclarion (ACON) Stock Conversion (Momentum Building) 2026-04-15Long Term Investing - Xã Vĩnh Công
Aclarion's AI Platform Nociscan Wins Pinnacle Award, Validating Approach to Chronic Low Back Pain Diagnosis - citybuzz -
Aclarion Receives Pinnacle Award for AI Innovation - The Manila Times
AI tool for chronic back pain earns Aclarion a second health tech award - Stock Titan
Aclarion (ACON) price target decreased by 69.57% to 7.14 - MSN
Take Profit: Will Opendoor Technologies Inc outperform the market in YEAR2026 Trading Recap & Verified Swing Trading Watchlist - baoquankhu1.vn
Will Aclarion (ACON) Stock Go Higher | Price at $3.80, Up 6.44%Seasonal Patterns - Cổng thông tin điện tử tỉnh Lào Cai
Aclarion Announces Agreement with Weill Cornell Medicine - Bitget
Aclarion establishes agreement with Weill Cornell Medicine By Investing.com - Investing.com Australia
Aclarion Partners with Weill Cornell Medicine to Expand Nociscan Use in Spine Pain Research - citybuzz -
Aclarion establishes agreement with Weill Cornell Medicine - Investing.com
1.66%
1.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):